York Based Medical Devices Company Signs US Distribution Contract
05 May 2015
York-based Tissue Regenix Group, the regenerative medical devices company, has signed a new US distribution contract with TRX Wound Care Inc. for DermaPure® - a product used in the treatment of chronic and acute wounds.
Commercial interest in Dermapure® has significantly increased following Novitas, a Medicare Administrative Contractor covering US states representing 8.9 million Medicare beneficiaries, gave it a Local Coverage Determination (LCD) earlier this year.
This latest new contract is worth a minimum of $600k andcovers the next 12 months and builds on the increasing clinical awareness of the outstanding results being achieved in the US by Dermapure®. Tissue Regenix is also continuing to deploy its direct sales representatives as part of its ‘hybrid’ distribution strategy of both direct and indirect sales representation.
Antony Odell, CEO of Tissue Regenix, commented: "Our US team has done an outstanding job in achieving commercial traction for DermaPure® and signing this regional distribution agreement.This agreement validates the hard work put in since the launch of DermaPure® in June 2014, as well as the remarkable clinical results that we are seeing from the product."